Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

HUMA
Humacyte, Inc. Common Stock
stock NASDAQ

Market Open
Aug 11, 2026 1:31:12 PM EDT
0.7200USD-2.486%(-0.0200)1,895,427
0.6400Bid   0.8400Ask   0.2100Spread
Pre-market
Aug 11, 2026 9:27:30 AM EDT
0.7409USD+0.122%(+0.0009)41,275
After-hours
Aug 10, 2026 4:48:30 PM EDT
0.7295USD-2.002%(-0.0149)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
07:34AM EST  Humacyte Announces Clinical Case Series Demonstrating Potential Of Human Acellular Vessel To Expand Opportunities For Limb Salvage In Multiple Complex Vascular Reconstruction Scenarios   Benzinga
07:30AM EST  Outcomes of first eight compassionate use cases presented at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society   GlobeNewswire Inc
Jan 28, 2022
09:16AM EST  Humacyte Announces Results From Preclinical Study Of Small-Diameter Human Acellular Vessel (HAV) In Coronary Artery Bypass Grafting   Benzinga
09:15AM EST  -- HAV remained patent and host-cell remodeling was observed in non-human primate model --   GlobeNewswire Inc
Jan 6, 2022
07:30AM EST  Humacyte Announces Presentation of First Eight Expanded Access   GlobeNewswire Inc
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Jan 4, 2022
07:46AM EST  Humacyte Highlights Presentation Of HAV Preclinical Results At Advanced Therapies Week Conference   Benzinga
07:30AM EST  Humacyte Announces Presentation of First Preclinical Results of   GlobeNewswire Inc
Dec 31, 2021
07:30AM EST  Humacyte Announces the Appointments of Three Surgical and   GlobeNewswire Inc
Dec 15, 2021
07:34AM EST  Humacyte Announces Publication Highlighting First Use Of Human Acellular Vessel As Arterial Bypass Conduit For Replacement Of Infected Prosthetic Graft   Benzinga
07:30AM EST  -- Vanderbilt University Medical Center patient received the HAV under the U.S. Food and Drug Administrations (FDA) Expanded Access Program (EAP) in April 2019 --   GlobeNewswire Inc
Nov 16, 2021
07:39AM EST  Humacyte Presents Preclinical Results Of Small-Diameter HAV For Use As A BTT Shunt In Pediatric Heart Disease At American Heart Association's Scientific Sessions 2021   Benzinga
07:30AM EST  -- Patency and host cell remodeling of the HAV were observed in all study implants   GlobeNewswire Inc
Nov 15, 2021
11:17AM EST  Humacyte Highlights Presentation Of 12-Month Data From Human Acellular Vessel Produced Using Commercial-Scale Manufacturing System   Benzinga
09:30AM EST  Performance of HAVs produced in the LUNA200commercial-scale system demonstrated efficacy that is similar to prior HAV performance in dialysis access trials   GlobeNewswire Inc
Nov 12, 2021
07:47AM EST  Humacyte Q3 EPS $(0.72) Up From $(3.07) YoY, Grant Sales $241.00K Down From $914.00K YoY   Benzinga
07:39AM EST  Humacyte Q3 Net Loss $31.6 Mln Or $0.72/Shr Vs Loss Of $17.8 Mln Or $3.07/Shr Last Year   RTTNews
07:30AM EST  -- Completed business combination with Alpha Healthcare Acquisition Corp. and raised $242M in proceeds --   GlobeNewswire Inc
Nov 9, 2021
07:30AM EST  Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the Credit Suisse 30th Annual Healthcare Conference taking place virtually, on Nov. 10, 2021, at 1 p.m. EST.   GlobeNewswire Inc
Nov 8, 2021
07:30AM EST  Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that leadership will present new data and additional information on its programs at several scientific events in November 2021.   GlobeNewswire Inc
Oct 29, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 29, 2021   Benzinga
06:53AM EDT  Cowen & Co. Initiates Coverage On Humacyte with Outperform Rating, Announces Price Target of $17   Benzinga
Oct 5, 2021
07:30AM EDT  Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that senior leadership will present at seven scientific and industry events in October 2021.   GlobeNewswire Inc
Sep 24, 2021
10:43AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021   Benzinga
05:23AM EDT  Oppenheimer Initiates Coverage On Humacyte with Outperform Rating, Announces Price Target of $16   Benzinga
Sep 22, 2021
10:05AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021   Benzinga
07:06AM EDT  BTIG Initiates Coverage On Humacyte with Buy Rating, Announces Price Target of $19   Benzinga
Sep 20, 2021
08:45AM EDT  Humacyte Announces Issuance Of Three Additional US Patents Covering Its Implantable Bioengineered Human Tissue Platform   Benzinga
08:45AM EDT  -- Patent estate also expanded by the issuance of 23 additional patents in international markets -- Humacyte now owns or licenses 119 patents covering its proprietary platform   GlobeNewswire Inc
Sep 17, 2021
07:53AM EDT  Humacyte Highlights List Of Sept. Presentations, Including Upcoming Events On Sept. 17, 23, 24   Benzinga
07:52AM EDT  Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that senior leadership will present at five scientific and medical events in September 2021.   GlobeNewswire Inc
Sep 16, 2021
02:27PM EDT  Humacyte shares were trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $17 price target.   Benzinga
10:07AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2021   Benzinga
05:03AM EDT  Piper Sandler Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $17   Benzinga
Sep 2, 2021
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC